Updating results

Nivolumab with radiation therapy for untreated glioblastoma ID1562

In development [GID-TA10443] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

In development [GID-TA10148] Expected publication date: TBC

Technology appraisal guidance In development

Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]

In development [GID-TA10361] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)

In development [GID-TA10233] Expected publication date: TBC

Technology appraisal guidance In development

Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]

In development [GID-TA10224] Expected publication date: TBC

Technology appraisal guidance In development

Multiple sclerosis - sativex [ID387]

In development [GID-TAG368] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470

In development [GID-TA10354] Expected publication date: TBC

Technology appraisal guidance In development

Short bowel syndrome - teduglutide [ID885]

In development [GID-TA10048] Expected publication date: TBC

Technology appraisal guidance In development

Glasdegib with chemotherapy for untreated acute myeloid leukaemia [ID1334]

In development [GID-TA10314] Expected publication date: TBC

Technology appraisal guidance In development

Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID1477]

In development [GID-TA10448] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Nivolumab in combination for untreated advanced gastric cancer [ID1465]

In development [GID-TA10352] Expected publication date: 14 July 2021

Technology appraisal guidance In development

Enzalutamide with androgen deprivation therapy for treating metastatic hormone-sensitive prostate cancer ID1605

In development [GID-TA10488] Expected publication date: 05 August 2020

Technology appraisal guidance In development

Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]

In development [GID-TA10504] Expected publication date: TBC

Technology appraisal guidance In development

Acalabrutinib for treating chronic lymphocytic leukaemia ID1613

In development [GID-TA10532] Expected publication date: TBC

Technology appraisal guidance In development

Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538

In development [GID-TA10422] Expected publication date: TBC

Technology appraisal guidance In development

Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib [ID883]

In development [GID-TA10045] Expected publication date: TBC

Technology appraisal guidance In development

Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]

In development [GID-TA10165] Expected publication date: TBC

Technology appraisal guidance In development

Melanoma (metastatic) - talimogene laherparepvec [ID508]

In development [GID-TAG509] Expected publication date: 28 September 2016

Technology appraisal guidance In development

KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609]

In development [GID-TAG321] Expected publication date: TBC

Technology appraisal guidance In development

Drisapersen for the first-line treatment of Duchenne's muscular dystrophy [ID911]

In development [GID-HST10004] Expected publication date: TBC

Highly specialised technologies guidance In development

Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]

In development [GID-TA10168] Expected publication date: TBC

Technology appraisal guidance In development

Enzalutamide for the treatment of hormone refractory prostate cancer TA316

In development [GID-TA10267] Expected publication date: TBC

Technology appraisal guidance In development

Moxetumomab pasudotox for hairy-cell leukaemia [ID1142]

In development [GID-TA10288] Expected publication date: TBC

Technology appraisal guidance In development

Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732]

In development [GID-TAG482] Expected publication date: TBC

Technology appraisal guidance In development

Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250

In development [GID-TA10213] Expected publication date: TBC

Technology appraisal guidance In development

Eteplirsen for treating Duchenne muscular dystrophy [ID1003]

In development [GID-HST10007] Expected publication date: TBC

Highly specialised technologies guidance In development

Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]

In development [GID-TAG507] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for previously treated multiple myeloma (ID1139)

In development [GID-TA10193] Expected publication date: TBC

Technology appraisal guidance In development

Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]

In development [GID-TAG511] Expected publication date: TBC

Technology appraisal guidance In development

Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]

In development [GID-TAG508] Expected publication date: TBC

Technology appraisal guidance In development

Microthane implants for breast reconstruction or breast augmentation (discontinued)

In development [GID-MT267] Expected publication date: TBC

Medical technologies guidance In development

Velmanase alfa for treating alpha-mannosidosis [ID800]

In development [GID-HST10010] Expected publication date: TBC

Highly specialised technologies guidance In development

SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)

In development [GID-MT526] Expected publication date: TBC

Medical technologies guidance In development

Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 23 September 2020

Technology appraisal guidance In development

Sapropterin for treating phenylketonuria [ID1475]

In development [GID-TA10378] Expected publication date: TBC

Technology appraisal guidance In development

Atezolizumab with nab-paclitaxel for treating PD L1-positive, triple-negative, advanced breast cancer [ID1522]

In development [GID-TA10433] Expected publication date: TBC

Technology appraisal guidance In development

Lisocabtagene maraleucel for treating large B-cell lymphoma after at least 2 therapies ID1444

In development [GID-TA10477] Expected publication date: TBC

Technology appraisal guidance In development

Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

In development [GID-TA10277] Expected publication date: TBC

Technology appraisal guidance In development

TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices [ID1440]

In development [GID-TA10370] Expected publication date: TBC

Technology appraisal guidance In development

Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Technology appraisal guidance In development

Naldemedine for treating opioid-induced constipation ID1189

In development [GID-TA10291] Expected publication date: 05 June 2020

Technology appraisal guidance In development

Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]

In development [GID-TA10550] Expected publication date: TBC

Technology appraisal guidance In development

Idebenone for treating Duchenne muscular dystrophy ID1092

In development [GID-TA10310] Expected publication date: TBC

Technology appraisal guidance In development

Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565

In development [GID-TA10502] Expected publication date: TBC

Technology appraisal guidance In development

Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466

In development [GID-TA10355] Expected publication date: TBC

Technology appraisal guidance In development

The Assurance Nasal Alar SpO2 Sensor (discontinued)

In development [GID-MT510] Expected publication date: TBC

Medical technologies guidance In development

Psoriasis - briakinumab (suspended) [ID65]

In development [GID-TAG412] Expected publication date: TBC

Technology appraisal guidance In development

Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305

In development [GID-TA10244] Expected publication date: TBC

Technology appraisal guidance In development

NBTXR-3 for treating soft tissue sarcoma [ID1050]

In development [GID-TA10226] Expected publication date: TBC

Technology appraisal guidance In development